MSP-133is also cleaved into two other fragments, MSP-114and MSP-120

MSP-133is also cleaved into two other fragments, MSP-114and MSP-120. In addition, the majority ofP. vivaxantigen candidates are polymorphic, induce strain-specific and heterogeneous immunity and provide only partial protection. Nevertheless, immunization with recombinant proteins Lanifibranor and multiantigen vaccines have shown promising results and have emerged as excellent strategies. However, more studies are necessary to assess the ideal vaccine combination and test it in clinical trials. Developing a safe and effective vaccine against vivax malaria is essential for controlling and eliminating the disease. Therefore, it is necessary to determine what is already known to propose and identify new candidates. Keywords:malaria,Plasmodium vivax, vaccine, subunit, vaccine candidates == 1. Introduction == Malaria has a devastating impact on peoples quality of life, mortality, and morbidity. In 2020, it caused more than 241 million cases worldwide and killed approximately 627 thousand people (1). It occurs in several tropical and subtropical regions, with a high incidence in sub-Saharan Africa, Southeast Asia, the Eastern Mediterranean, the Western Pacific, and the Americas (1). It is caused byPlasmodiumspp. And transmitted during the blood meals of infected females ofAnophelesspp. Mosquitoes. Seven species ofPlasmodiumaffect humans:P. falciparum,P. vivax,P. malariae,P. ovale,P. knowlesi,P. cynomolgyandP. simium, of whichP. falciparumandP. vivaxare responsible for approximately 99% of malaria cases. AlthoughP. falciparumis the deadliest parasite,P. vivaxis the most geographically spread (1). P. vivaxwas neglected for decades because of the belief that its infection causes milder disease (2). However, recent studies reported severe cases caused by vivax malaria, such as severe anemia, cerebral malaria, thrombocytopenia, and acute respiratory syndrome (39). Studies have shown thatP. vivaxhas the ability to promote cytoadherence to the hosts endothelium and form rosettes (1012), features frequently associated Lanifibranor with severeP. falciparummalaria (13,14). Nevertheless, due to the numerous challenges that this parasite poses, there are few vaccines under development (15). The development of a safe and effective vaccine against Cst3 malaria is the best and most relevant strategy for preventing, controlling, and eliminating malaria. However, we are still far from achieving this, especially for vivax malaria (16). Lanifibranor The difficulty in finding the best immunogen combined in a formulation that induces protection is the main challenge in vivax vaccines. The majority of experimental vaccines againstP. vivaxcontain a recombinantP. vivaxprotein with an adjuvant. In addition, different technologies have been used in an attempt to improve malaria vaccine efficacy, such as recombinant viral vectors, virus-like particles (VLPs), DNA plasmids, long synthetic peptides (LSPs) and irradiation-attenuated parasites. However, they all failed to induce a strong protective effect. ForP. falciparummalaria prevention, a vaccine called Mosquirix (RTS, S) was recently approved for children (ClinicalTrials.gov Lanifibranor number,NCT00380393). The RTS/S is a subunit vaccine that targets the central repeats and the C-terminal of theP. falciparumcircumsporozoite surface protein (PfCSP), including T-cell epitopes (T) fused to hepatitis B surface antigen (HBsAg) (S), mixed with native HBsAg (S), formulated with the AS01 adjuvant. The vaccine efficacy against clinical malaria over 4 years of follow-up was estimated at 25.9% in infants and at 36,3% in children, but as the age and time of vaccination advance, the estimative drops to low levels (17,18). Over 7 years of follow-up, the efficacy was estimated at 4.4% (19). R21/MatrixM is a vaccine candidate in the approval process (ClinicalTrials.gov number,NCT03896724) with promising results of 77% efficacy Lanifibranor in phase III studies (20). However, forP. vivax, the scenario is meagre. To this parasite, there.